在接受blinatumomab治疗的微小残留病阳性B前体急性淋巴细胞白血病患者中血清免疫球蛋白水平的长期随访 - Suppr

Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia.

作者信息

Zugmaier G, Topp M S, Alekar S, Viardot A, Horst H-A, Neumann S, Stelljes M, Bargou R C, Goebeler M, Wessiepe D, Degenhard E, Gökbuget N, Klinger M

机构信息

Amgen Research (Munich) GmbH, Munich, Germany.

1] Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany [2] Comprehensive Cancer Center Mainfranken, Universitätsklinikum Würzburg, Würzburg, Germany.

出版信息

Blood Cancer J. 2014 Sep 5;4(9):244. doi: 10.1038/bcj.2014.64.

DOI:10.1038/bcj.2014.64

PMID:25192414

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4183773/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a1e/4183773/2a2ed0e21e1a/bcj201464f1.jpg

相似文献

Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia.

Blood Cancer J. 2014 Sep 5;4(9):244. doi: 10.1038/bcj.2014.64.

Blinatumomab activity in a patient with Down syndrome B-precursor acute lymphoblastic leukemia.

Pediatr Blood Cancer. 2018 Feb;65(2). doi: 10.1002/pbc.26824. Epub 2017 Sep 17.

Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.

Haematologica. 2014 Jul;99(7):1212-9. doi: 10.3324/haematol.2013.100073. Epub 2014 Apr 11.

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.

Blood. 2018 Apr 5;131(14):1522-1531. doi: 10.1182/blood-2017-08-798322. Epub 2018 Jan 22.

Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.

Oncologist. 2020 Apr;25(4):e709-e715. doi: 10.1634/theoncologist.2019-0559. Epub 2019 Nov 14.

Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.

Blood. 2015 Dec 10;126(24):2578-84. doi: 10.1182/blood-2015-06-649111. Epub 2015 Oct 19.

A closer look at blinatumomab.

Clin Adv Hematol Oncol. 2018 Jun;16(6):412-414.

Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies.

Clin Pharmacokinet. 2020 Apr;59(4):463-474. doi: 10.1007/s40262-019-00823-8.

Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.

Ann Hematol. 2020 Oct;99(10):2215-2229. doi: 10.1007/s00277-020-04221-0. Epub 2020 Aug 27.

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

Lancet Oncol. 2015 Jan;16(1):57-66. doi: 10.1016/S1470-2045(14)71170-2. Epub 2014 Dec 16.

引用本文的文献

Blinatumomab use in pediatric B-ALL: where are we now?

Blood Adv. 2025 Aug 12;9(15):3946-3954. doi: 10.1182/bloodadvances.2024014043.

Blinatumomab in Children with MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia: A Report of 11 Cases.

Hematol Rep. 2024 Jun 3;16(2):347-353. doi: 10.3390/hematolrep16020035.

Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia.

Haematologica. 2024 Jun 1;109(6):1700-1712. doi: 10.3324/haematol.2023.283815.

Risk of Severe Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies.

Cureus. 2024 Jan 10;16(1):e52050. doi: 10.7759/cureus.52050. eCollection 2024 Jan.

Case Report: Blinatumomab as upfront consolidation and maintenance therapy in a pediatric patient with high-risk B-cell acute lymphoblastic leukemia.

Front Oncol. 2023 Nov 1;13:1246924. doi: 10.3389/fonc.2023.1246924. eCollection 2023.

Short-course blinatumomab for refractory/relapse precursor B acute lymphoblastic leukemia in children.

Front Pediatr. 2023 Aug 4;11:1187607. doi: 10.3389/fped.2023.1187607. eCollection 2023.

Risk of Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies.

Life (Basel). 2023 May 28;13(6):1272. doi: 10.3390/life13061272.

COVID-19 infection during blinatumomab therapy: Is safety a dilemma?

SAGE Open Med Case Rep. 2023 Jan 10;11:2050313X221148548. doi: 10.1177/2050313X221148548. eCollection 2023.

Acute Kidney Injury in Cancer Immunotherapy Recipients.

Cells. 2022 Dec 10;11(24):3991. doi: 10.3390/cells11243991.

Severe coronavirus HCoV-NL63 pneumonia in a patient receiving blinatumomab with secondary antibody deficiency in COVID-19 times.

Germs. 2022 Jun 30;12(2):292-297. doi: 10.18683/germs.2022.1331. eCollection 2022 Jun.

本文引用的文献

B-cell targeted therapeutics in clinical development.

Arthritis Res Ther. 2013;15 Suppl 1(Suppl 1):S4. doi: 10.1186/ar3906. Epub 2013 Apr 4.

Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections.

Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):106-11. doi: 10.1016/j.clml.2012.11.011. Epub 2012 Dec 29.

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.

Blood. 2012 Dec 20;120(26):5185-7. doi: 10.1182/blood-2012-07-441030. Epub 2012 Sep 28.

Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides.

PLoS One. 2012;7(5):e37626. doi: 10.1371/journal.pone.0037626. Epub 2012 May 21.

Impact of treatment reduction for childhood acute lymphoblastic leukemia on serum immunoglobulins and antibodies against vaccine-preventable diseases.

Pediatr Blood Cancer. 2012 May;58(5):701-7. doi: 10.1002/pbc.23258. Epub 2011 Jul 25.

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

J Clin Oncol. 2011 Jun 20;29(18):2493-8. doi: 10.1200/JCO.2010.32.7270. Epub 2011 May 16.

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.

J Clin Oncol. 2010 Jun 10;28(17):2853-8. doi: 10.1200/JCO.2009.26.5827. Epub 2010 May 3.

Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis.

Int J Hematol. 2010 Apr;91(3):501-8. doi: 10.1007/s12185-010-0528-6. Epub 2010 Mar 10.

Does rituximab aggravate pre-existing hypogammaglobulinaemia?

J Clin Pathol. 2010 Mar;63(3):275-7. doi: 10.1136/jcp.2009.068940.

Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma.

Ann Oncol. 2010 Jun;21(6):1203-1210. doi: 10.1093/annonc/mdp484. Epub 2009 Oct 30.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia.

作者信息

Zugmaier G, Topp M S, Alekar S, Viardot A, Horst H-A, Neumann S, Stelljes M, Bargou R C, Goebeler M, Wessiepe D, Degenhard E, Gökbuget N, Klinger M

机构信息

Amgen Research (Munich) GmbH, Munich, Germany.

1] Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany [2] Comprehensive Cancer Center Mainfranken, Universitätsklinikum Würzburg, Würzburg, Germany.

出版信息

Blood Cancer J. 2014 Sep 5;4(9):244. doi: 10.1038/bcj.2014.64.

DOI:10.1038/bcj.2014.64

PMID:25192414

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4183773/

Abstract

摘要

相似文献

Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia.

Blood Cancer J. 2014 Sep 5;4(9):244. doi: 10.1038/bcj.2014.64.

Blinatumomab activity in a patient with Down syndrome B-precursor acute lymphoblastic leukemia.

Pediatr Blood Cancer. 2018 Feb;65(2). doi: 10.1002/pbc.26824. Epub 2017 Sep 17.

Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.

Haematologica. 2014 Jul;99(7):1212-9. doi: 10.3324/haematol.2013.100073. Epub 2014 Apr 11.

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.

Blood. 2018 Apr 5;131(14):1522-1531. doi: 10.1182/blood-2017-08-798322. Epub 2018 Jan 22.

Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.

Oncologist. 2020 Apr;25(4):e709-e715. doi: 10.1634/theoncologist.2019-0559. Epub 2019 Nov 14.

Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.

Blood. 2015 Dec 10;126(24):2578-84. doi: 10.1182/blood-2015-06-649111. Epub 2015 Oct 19.

A closer look at blinatumomab.

Clin Adv Hematol Oncol. 2018 Jun;16(6):412-414.

Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies.

Clin Pharmacokinet. 2020 Apr;59(4):463-474. doi: 10.1007/s40262-019-00823-8.

Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.

Ann Hematol. 2020 Oct;99(10):2215-2229. doi: 10.1007/s00277-020-04221-0. Epub 2020 Aug 27.

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

Lancet Oncol. 2015 Jan;16(1):57-66. doi: 10.1016/S1470-2045(14)71170-2. Epub 2014 Dec 16.

引用本文的文献

Blinatumomab use in pediatric B-ALL: where are we now?

Blood Adv. 2025 Aug 12;9(15):3946-3954. doi: 10.1182/bloodadvances.2024014043.

Blinatumomab in Children with MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia: A Report of 11 Cases.

Hematol Rep. 2024 Jun 3;16(2):347-353. doi: 10.3390/hematolrep16020035.

Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia.

Haematologica. 2024 Jun 1;109(6):1700-1712. doi: 10.3324/haematol.2023.283815.

Risk of Severe Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies.

Cureus. 2024 Jan 10;16(1):e52050. doi: 10.7759/cureus.52050. eCollection 2024 Jan.

Case Report: Blinatumomab as upfront consolidation and maintenance therapy in a pediatric patient with high-risk B-cell acute lymphoblastic leukemia.

Front Oncol. 2023 Nov 1;13:1246924. doi: 10.3389/fonc.2023.1246924. eCollection 2023.

Short-course blinatumomab for refractory/relapse precursor B acute lymphoblastic leukemia in children.

Front Pediatr. 2023 Aug 4;11:1187607. doi: 10.3389/fped.2023.1187607. eCollection 2023.

Risk of Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies.

Life (Basel). 2023 May 28;13(6):1272. doi: 10.3390/life13061272.

COVID-19 infection during blinatumomab therapy: Is safety a dilemma?

SAGE Open Med Case Rep. 2023 Jan 10;11:2050313X221148548. doi: 10.1177/2050313X221148548. eCollection 2023.

Acute Kidney Injury in Cancer Immunotherapy Recipients.

Cells. 2022 Dec 10;11(24):3991. doi: 10.3390/cells11243991.

Severe coronavirus HCoV-NL63 pneumonia in a patient receiving blinatumomab with secondary antibody deficiency in COVID-19 times.

Germs. 2022 Jun 30;12(2):292-297. doi: 10.18683/germs.2022.1331. eCollection 2022 Jun.

本文引用的文献

B-cell targeted therapeutics in clinical development.

Arthritis Res Ther. 2013;15 Suppl 1(Suppl 1):S4. doi: 10.1186/ar3906. Epub 2013 Apr 4.

Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections.

Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):106-11. doi: 10.1016/j.clml.2012.11.011. Epub 2012 Dec 29.

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.

Blood. 2012 Dec 20;120(26):5185-7. doi: 10.1182/blood-2012-07-441030. Epub 2012 Sep 28.

Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides.

PLoS One. 2012;7(5):e37626. doi: 10.1371/journal.pone.0037626. Epub 2012 May 21.

Impact of treatment reduction for childhood acute lymphoblastic leukemia on serum immunoglobulins and antibodies against vaccine-preventable diseases.

Pediatr Blood Cancer. 2012 May;58(5):701-7. doi: 10.1002/pbc.23258. Epub 2011 Jul 25.

J Clin Oncol. 2011 Jun 20;29(18):2493-8. doi: 10.1200/JCO.2010.32.7270. Epub 2011 May 16.

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.

J Clin Oncol. 2010 Jun 10;28(17):2853-8. doi: 10.1200/JCO.2009.26.5827. Epub 2010 May 3.

Int J Hematol. 2010 Apr;91(3):501-8. doi: 10.1007/s12185-010-0528-6. Epub 2010 Mar 10.

Does rituximab aggravate pre-existing hypogammaglobulinaemia?

J Clin Pathol. 2010 Mar;63(3):275-7. doi: 10.1136/jcp.2009.068940.

Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma.

Ann Oncol. 2010 Jun;21(6):1203-1210. doi: 10.1093/annonc/mdp484. Epub 2009 Oct 30.

Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献